Patricia Ganz, MD

Dr. Patricia Ganz has spent the past three decades studying the quality of life outcomes for patients with cancer. She is a leader in the integration of patient reported outcomes in clinical trials, and currently co-chairs the Patient Centered Outcomes Research Committee of NRG Oncology. In recent years her laboratory has focused on developing and testing interventions to reduce the late medical effects of treatment in women with breast cancer (for example, menopause, osteoporosis, fatigue and cognitive changes). Ganz and her associates are examining fatigue, sleep and cognitive functioning in a variety of studies, and are exploring the immunological and physiological mechanisms underlying these issues. Current research studies focus on testing strategies to improve cognitive changes in breast cancer survivors, and another study focuses on reducing stress and improving health outcomes in younger women with breast cancer.

Ganz is also a national leader in efforts to improve the delivery of quality cancer care to patients. At UCLA she leads the cancer survivorship program, and provides clinical consultation to survivors of childhood and adult cancers. She has been a member of the National Academy of Medicine (formerly the Institute of Medicine) since 2007, and was a member of the National Cancer Policy Forum from 2006 to 2016. Ganz has extensive scientific and editorial experience, and recently was named as Editor-in-Chief of the Journal of the National Cancer Institute.

Nekhlyudov L, Ganz PA, Arora NK, Rowland JH. Going Beyond Being Lost in Transition: A Decade of Progress in Cancer Survivorship. J Clin Oncol. 2017 Jun 20;35(18):1978-1981. doi: 10.1200/JCO.2016.72.1373. Epub 2017 Apr 24.

Maly RC, Liang LJ, Liu Y, Griggs JJ, Ganz PA. Randomized Controlled Trial of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors. J Clin Oncol. 2017 Jun 1;35(16):1814-1821. doi: 10.1200/JCO.2016.68.9497. Epub 2017 Apr 18.

Ganz PA, Petersen L, Bower JE, Crespi CM. Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. J Clin Oncol. 2016 Mar 10;34(8):816-24. doi: 10.1200/JCO.2015.64.3866. Epub 2016 Jan 19.

Long EF, Ganz PA. Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making. JAMA Oncol. 2015 Dec;1(9):1217-8. doi: 10.1001/jamaoncol.2015.2340.

Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016 Feb 27;387(10021):857-65. doi: 10.1016/S0140-6736(15)01169-1. Epub 2015 Dec 11.